Overview
Diabetes Mellitus: Prevention strategies, predictors, treatment effects; kidney and other complications including cardiovascular outcomes. Utilization of EHR data to construct tools to improve the care of diabetes and comorbid conditions.
Current Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Endocrinology, Metabolism, and Nutrition,
Medicine
Member in the Duke Clinical Research Institute
·
2008 - Present
Duke Clinical Research Institute,
Institutes and Centers
Recent Publications
Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial.
Journal Article Eur J Prev Cardiol · January 6, 2026 AIMS: Atrial fibrillation and flutter (AF) are common in patients with Type 2 diabetes and are associated with worse outcomes. METHODS AND RESULTS: Harmony Outcomes was a multi-centre, event-driven, double-blind, placebo-controlled trial comparing the effe ... Full text Link to item CiteImpact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.
Journal Article Clin J Am Soc Nephrol · January 1, 2026 Full text Link to item CiteSimultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.
Journal Article Nephrol Dial Transplant · December 23, 2025 BACKGROUND: The CONFIDENCE (COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with CKD and type 2 diabetes using a UACR Endpoint) trial investigated the safety and efficacy of simultaneously initiating finerenone and empagliflozin for pati ... Full text Link to item CiteRecent Grants
GentiBio_GNTI-122-T1D-1001
Clinical TrialPrincipal Investigator · Awarded by GentiBio, Inc. · 2025 - 2035A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 with Recent Onset Stage 3 Type 1 Diabetes
Clinical TrialPrincipal Investigator · Awarded by COUR Pharmaceuticals Development Co., Inc. · 2025 - 2034Endocrinology and Metabolism Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2029View All Grants
Education, Training & Certifications
University of Virginia ·
1993
M.D.